Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2699-2705

  Feng, Gege ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic lymphocytic leukemia; Syk; Syk inhibitors; ZAP 70

Indexed keywords

ANTIGEN; B LYMPHOCYTE RECEPTOR; FOSTAMATINIB; IMMUNOGLOBULIN HEAVY CHAIN; P 505 15; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE ZAP 70; PRT 318; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

APOPTOSIS; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; CORRELATIONAL STUDY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; LEUKEMIA CELL; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84919461566     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.891026     Document Type: Review

References (75)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
2. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 2009; 69: 2415-2449.
3. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387-402.
4. Hoellenriegel J, Cof ey GP, Sinha U, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012;26:1576-1583.
5. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specif c targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029-1037.
6. Spurgeon SE, Cof ey G, Fletcher LB, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of f udarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ter 2013;344:378-387.
7. Pierce SK, Liu W. The tipping points in the initiation of B cell signalling: how small changes make big dif erences. Nat Rev Immunol 2010;10:767-777.
8. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313-4320.
9. Darzentas N, Stamatopoulos K. Stereotyped B cell receptors in B cell leukemias and lymphomas. Methods Mol Biol 2013; 971: 135-148.
10. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classif cation with implications for targeted therapies. Blood 2012; 119: 4467-4475.
11. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524-1533.
12. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259-270.
13. Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013; 210: 59-70.
14. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005;201:1229-1241.
15. Craig VJ, Cogliatti SB, Arnold I, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010; 24: 1186-1196.
16. Hoogeboom R, Bende RJ, vanNoesel CJ. MALTlymphoma-derived rheumatoid factors are nonpolyreactive high-afnity antibodies. Blood 2010;116:1818-1819; author reply 1819-1820.
17. Hussell T, Isaacson PG, Crabtree JE, et al. Helicobacter pylori-specif c tumour-inf ltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178:122-127.
18. Duhren-von Minden M, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012;489:309-312.
19. Binder M, Muller F, Frick M, et al. CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood 2013;121:239-241.
20. Chiorazzi N, Efremov DG. Chronic lymphocytic leukemia: a tale of one or two signals? Cell Res 2013; 23: 182-185.
21. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002;2:945-956.
22. Geahlen RL. Syk and pTyr'd: Signaling through the B cell antigen receptor. Biochim Biophys Acta 2009;1793:1115-1127.
23. Bellacosa A, Chan TO, Ahmed NN, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998;17:313-325.
24. Hashimoto A, Okada H, Jiang A, et al. Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med 1998;188:1287-1295.
25. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
26. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-3513.
27. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-747.
28. Ruland J, Mak TW. Transducing signals from antigen receptors to nuclear factor kappaB. Immunol Rev 2003; 193: 93-100.
29. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977-2986.
30. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has signif cant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
31. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood 2010;116(Suppl. 1): Abstract 964.
32. O'Brien S, Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. Blood 2011; 118(Suppl. 1): Abstract 983.
33. Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2011; 29(Suppl.): Abstract 6631.
34. Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K delta) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2011;118(Suppl.1): Abstract 2699.
35. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006; 6: 283-294.
36. Carsetti L, Laurenti L, Gobessi S, et al. Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. Cell Signal 2009;21:1187-1194.
37. Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009;113:2508-2516.
38. Delgado P, Cubelos B, Calleja E, et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol 2009;10:880-888.
39. Longo P G, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-855.
40. Pogue SL, Kurosaki T, Bolen J, et al. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J Immunol 2000; 165: 1300-1306.
41. Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009;139:573-586.
42. Vallat LD, Park Y, Li C, et al. Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood 2007; 109:3989-3997.
43. Buchner M, Fuchs S, Prinz G, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009;69:5424-5432.
44. Wang YH, Fan L, Wang L, et al. Expression levels of Lyn, Syk, PLCgamma2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival. Leuk Lymphoma 2013;54:1165-1170.
45. Philippen A, Diener S, Zenz T, et al. SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). Br J Haematol 2010;150:633-636.
46. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008;111:2685-2692.
47. Gobessi S, Laurenti L, Longo PG, et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inef cient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007;109:2032-2039.
48. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
49. Gobessi S, Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23:686-697.
50. Baudot AD, Jeandel PY, Mouska X, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009;28:3261-3273.
51. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005; 105: 4820-4827.
52. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inf ammation. J Pharmacol Exp Ter 2006;319:998-1008.
53. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in dif use large B-cell lymphoma. Blood 2008; 111: 2230-2237.
54. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-3058.
55. Tohyama Y, Yamamura H. Protein tyrosine kinase, syk: a key player in phagocytic cells. J Biochem 2009; 145: 267-273.
56. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine-and integrin-mediated stromal protective ef ects in chronic lymphocytic leukemia. Blood 2010; 115:4497-4506.
57. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 3309-3318.
58. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-1312.
59. Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010; 116: 4894-4905.
60. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006;103:11713-11718.
61. Cofey G, DeGuzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inf ammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ter 2012; 340: 350-359.
62. Reilly MP, Sinha U, Andre P, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 2011;117:2241-2246.
63. Chen YH, Peterson LC, Dittmann D, et al. Comparative analysis of f ow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol 2007;127:182-191.
64. Cruse JM, Lewis RE, Webb RN, et al. Zap-70 and CD38 as predictors of IgVH mutation in CLL. Exp Mol Pathol 2007; 83: 459-461.
65. Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110:4012-4021.
66. Kern W, Dicker F, Schnittger S, et al. Correlation of f ow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1, 229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 2009;76:385-393.
67. Hus I, Bojarska-Junak A, Dmoszynska A, et al. ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. Folia Histochem Cytobiol 2008; 46: 147-152.
68. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112: 1923-1930.
69. Trojani A, Montillo M, Nichelatti M, et al. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia. Cancer Biomark 2010;6:1-9.
70. Morilla A, Gonzalez de Castro D, Del Giudice I, et al.Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to frst treatment in CLL. Leuk Lymphoma 2008;49:2108-2115.
71. Laurenti L, Petlickovski A, Rumi C, et al. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica 2005; 90: 1533-1540.
72. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609-4614.
73. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036-2041.
74. Wang H, Kadlecek TA, Au-Yeung BB, et al. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol 2010;2:A002279.
75. Kaplan D, Meyerson HJ, Li X, et al. Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL. Cytometry B Clin Cytom 2010; 78: 115-122.